CAR--话题@MedSci

#CAR-#

459篇内容 | 2276人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1781328, encodeId=96a31e81328a0, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Nature：揭秘CAR-T疗法T细胞耗揭的关键原因，有望进一步攻克实体瘤！, objectType=article, longId=184589, objectId=745f18458941, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=745f18458941, replyNumber=0, likeNumber=64, createdTime=2020-11-13, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=745f18458941, moduleTitle=Nature：揭秘CAR-T疗法T细胞耗揭的关键原因，有望进一步攻克实体瘤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=745f18458941)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781326, encodeId=49921e813265c, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果, objectType=article, longId=184397, objectId=4dad18439e2a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dad18439e2a, replyNumber=0, likeNumber=57, createdTime=2020-03-23, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dad18439e2a, moduleTitle=百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4dad18439e2a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781305, encodeId=ab381e8130571, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解, objectType=article, longId=173300, objectId=ce3d1e330034, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce3d1e330034, replyNumber=0, likeNumber=60, createdTime=2020-04-21, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce3d1e330034, moduleTitle=Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce3d1e330034)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781279, encodeId=67471e8127916, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=日本即将批准诺华CAR-T药物Kymriah上市，可能纳入日本国民健康保险系统, objectType=article, longId=160817, objectId=c87c16081ebb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c87c16081ebb, replyNumber=0, likeNumber=77, createdTime=2019-03-26, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c87c16081ebb, moduleTitle=日本即将批准诺华CAR-T药物Kymriah上市，可能纳入日本国民健康保险系统, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c87c16081ebb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781300, encodeId=829a1e813001e, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=ASGCT：上海斯丹赛公布其装载PD-1拮抗分子CAR-T细胞疗法治疗淋巴瘤患者的临床数据, objectType=article, longId=165949, objectId=e85d1659491a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e85d1659491a, replyNumber=0, likeNumber=60, createdTime=2019-10-16, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e85d1659491a, moduleTitle=ASGCT：上海斯丹赛公布其装载PD-1拮抗分子CAR-T细胞疗法治疗淋巴瘤患者的临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e85d1659491a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781325, encodeId=1cbd1e813252f, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Cell：CAR-T被改造后有望攻克艾滋病, objectType=article, longId=184016, objectId=50bb184016f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50bb184016f2, replyNumber=0, likeNumber=78, createdTime=2020-01-13, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50bb184016f2, moduleTitle=Cell：CAR-T被改造后有望攻克艾滋病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50bb184016f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781277, encodeId=d2be1e812777f, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Clin Cancer Res:一种CAR-T疗法，对抗多种儿童肿瘤, objectType=article, longId=159261, objectId=cbf7159261e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbf7159261e9, replyNumber=0, likeNumber=71, createdTime=2019-08-05, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbf7159261e9, moduleTitle=Clin Cancer Res:一种CAR-T疗法，对抗多种儿童肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbf7159261e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781285, encodeId=1a2f1e81285fd, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=同种异体CAR-T细胞疗法开发公司Cellectis同时在巴黎和美国建立大型厂房, objectType=article, longId=162211, objectId=77bb16221122, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77bb16221122, replyNumber=0, likeNumber=67, createdTime=2019-08-21, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77bb16221122, moduleTitle=同种异体CAR-T细胞疗法开发公司Cellectis同时在巴黎和美国建立大型厂房, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77bb16221122)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781304, encodeId=64681e813040b, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=信达生物与驯鹿医疗联合开发的BCMA CAR-T临床数据亮相ASCO和EHA, objectType=article, longId=168735, objectId=7d54168e353a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d54168e353a, replyNumber=0, likeNumber=67, createdTime=2020-05-28, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d54168e353a, moduleTitle=信达生物与驯鹿医疗联合开发的BCMA CAR-T临床数据亮相ASCO和EHA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d54168e353a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781282, encodeId=eab51e81282e2, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Cell Medica获资助870万美元用于CAR-NKT细胞疗法的癌症治疗研究, objectType=article, longId=161428, objectId=a4b81614287d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4b81614287d, replyNumber=0, likeNumber=68, createdTime=2019-09-27, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4b81614287d, moduleTitle=Cell Medica获资助870万美元用于CAR-NKT细胞疗法的癌症治疗研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4b81614287d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781302, encodeId=95f91e8130256, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=如何打造更高效的CAR-T细胞产业？, objectType=article, longId=167096, objectId=350916e09623, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=350916e09623, replyNumber=0, likeNumber=51, createdTime=2019-12-08, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=350916e09623, moduleTitle=如何打造更高效的CAR-T细胞产业？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=350916e09623)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781316, encodeId=52ca1e81316dc, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Carl June联合创立的Tmunity获费城儿童医院**许可，推进GPC2 CAR-T用于神经母细胞瘤的治疗, objectType=article, longId=181022, objectId=9f2c18102286, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f2c18102286, replyNumber=0, likeNumber=80, createdTime=2020-05-04, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f2c18102286, moduleTitle=Carl June联合创立的Tmunity获费城儿童医院**许可，推进GPC2 CAR-T用于神经母细胞瘤的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f2c18102286)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781278, encodeId=2bc81e8127870, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Blood：CD19 CAR-T细胞疗法明显提高ALL患者的无事件存活期, objectType=article, longId=159703, objectId=2590159e03b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2590159e03b3, replyNumber=0, likeNumber=84, createdTime=2019-06-16, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2590159e03b3, moduleTitle=Blood：CD19 CAR-T细胞疗法明显提高ALL患者的无事件存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2590159e03b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781269, encodeId=65461e812697b, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=王建祥：CAR-T治疗的安全性与应用, objectType=article, longId=155534, objectId=1c5c155534fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c5c155534fa, replyNumber=0, likeNumber=86, createdTime=2019-03-01, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c5c155534fa, moduleTitle=王建祥：CAR-T治疗的安全性与应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c5c155534fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781309, encodeId=c5881e81309cf, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=TCR-T——CAR-T细胞治疗后新一代抗肿瘤利器, objectType=article, longId=177005, objectId=aca81e700547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aca81e700547, replyNumber=0, likeNumber=76, createdTime=2019-12-24, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aca81e700547, moduleTitle=TCR-T——CAR-T细胞治疗后新一代抗肿瘤利器, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aca81e700547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781311, encodeId=d1ba1e81311c4, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CARsgen Therapeutics公司的多发性骨髓瘤CAR-T细胞疗法喜获FDA的孤儿药物指定, objectType=article, longId=178782, objectId=c6a71e8782a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6a71e8782a5, replyNumber=0, likeNumber=98, createdTime=2019-11-17, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6a71e8782a5, moduleTitle=CARsgen Therapeutics公司的多发性骨髓瘤CAR-T细胞疗法喜获FDA的孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6a71e8782a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781272, encodeId=59c01e81272ce, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Gocar-T细胞在晚期胰腺肿瘤中显示出临床益处, objectType=article, longId=155931, objectId=9ccf1559311c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ccf1559311c, replyNumber=0, likeNumber=51, createdTime=2019-06-04, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ccf1559311c, moduleTitle=Gocar-T细胞在晚期胰腺肿瘤中显示出临床益处, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ccf1559311c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781275, encodeId=028f1e81275a0, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=CAR-T治疗复发难治急性B淋巴细胞白血病缓解率高, objectType=article, longId=156549, objectId=961e1565496f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=961e1565496f, replyNumber=0, likeNumber=80, createdTime=2019-11-14, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=961e1565496f, moduleTitle=CAR-T治疗复发难治急性B淋巴细胞白血病缓解率高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=961e1565496f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781296, encodeId=385c1e812967f, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=NAT MED：北大肿瘤医院突破CAR-T疗法瓶颈，有望变革治疗格局, objectType=article, longId=164862, objectId=1f7516486296, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f7516486296, replyNumber=0, likeNumber=50, createdTime=2019-06-28, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f7516486296, moduleTitle=NAT MED：北大肿瘤医院突破CAR-T疗法瓶颈，有望变革治疗格局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f7516486296)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1781313, encodeId=616c1e8131357, content=<a href='/topic/show?id=8ce8405907' target=_blank style='color:#2F92EE;'>#CAR-#</a>, objectTitle=Precision宣布FDA批准其靶向CD20的同种异体CAR-T细胞疗法PBCAR20A的研究新药申请IND, objectType=article, longId=179626, objectId=eba11e962686, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eba11e962686, replyNumber=0, likeNumber=62, createdTime=2020-06-13, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eba11e962686, moduleTitle=Precision宣布FDA批准其靶向CD20的同种异体CAR-T细胞疗法PBCAR20A的研究新药申请IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eba11e962686)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CAR-

2020-05-29

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Nature：揭秘CAR-T疗法T细胞耗揭的关键原因，有望进一步攻克实体瘤！

2020-11-13

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

百时美施贵宝和蓝鸟生物报告其CAR-T细胞疗法候选药物idecabtagene vicleucel的阳性结果

2020-03-23

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Blood：CD19 CAR-T细胞免疫疗法有助于难治性/复发性滤泡性淋巴瘤患者获得持久的缓解

2020-04-21

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

日本即将批准诺华CAR-T药物Kymriah上市，可能纳入日本国民健康保险系统

2019-03-26

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

ASGCT：上海斯丹赛公布其装载PD-1拮抗分子CAR-T细胞疗法治疗淋巴瘤患者的临床数据

2019-10-16

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Cell：CAR-T被改造后有望攻克艾滋病

2020-01-13

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

Clin Cancer Res:一种CAR-T疗法，对抗多种儿童肿瘤

2019-08-05

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

同种异体CAR-T细胞疗法开发公司Cellectis同时在巴黎和美国建立大型厂房

2019-08-21

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

信达生物与驯鹿医疗联合开发的BCMA CAR-T临床数据亮相ASCO和EHA

2020-05-28

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

Cell Medica获资助870万美元用于CAR-NKT细胞疗法的癌症治疗研究

2019-09-27

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

如何打造更高效的CAR-T细胞产业？

2019-12-08

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Carl June联合创立的Tmunity获费城儿童医院**许可，推进GPC2 CAR-T用于神经母细胞瘤的治疗

2020-05-04

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

Blood：CD19 CAR-T细胞疗法明显提高ALL患者的无事件存活期

2019-06-16

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

王建祥：CAR-T治疗的安全性与应用

2019-03-01

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

TCR-T——CAR-T细胞治疗后新一代抗肿瘤利器

2019-12-24

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

CARsgen Therapeutics公司的多发性骨髓瘤CAR-T细胞疗法喜获FDA的孤儿药物指定

2019-11-17

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

Gocar-T细胞在晚期胰腺肿瘤中显示出临床益处

2019-06-04

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

CAR-T治疗复发难治急性B淋巴细胞白血病缓解率高

2019-11-14

仁心济世 (审核中...)

前往app查看评论内容

#CAR-#

NAT MED：北大肿瘤医院突破CAR-T疗法瓶颈，有望变革治疗格局

2019-06-28

仁者大医 (审核中...)

前往app查看评论内容

#CAR-#

Precision宣布FDA批准其靶向CD20的同种异体CAR-T细胞疗法PBCAR20A的研究新药申请IND

2020-06-13

科室
- - 订阅+
  - 更多科室
工具
服务